Literature DB >> 25541255

Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ).

Oliver Ristow1, Sven Otto2, Matthias Troeltzsch2, Bettina Hohlweg-Majert3, Christoph Pautke4.   

Abstract

The medication-related osteonecrosis of the jaw (MRONJ) is believed to be a therapy-resistant entity. Although the application of the recommended conservative and surgical treatment regimens have returned variable success rates, the increased awareness and experience with MRONJ suggests that surgical therapy can halt the progression of the disease, thereby allowing a histology-based diagnosis of the osteonecrosis. Surgical treatment protocols can achieve success rates of over 90% and novel techniques such as the visualization of bone fluorescence can assist in the intra-operative delineation of the osteonecrosis and standardize the procedure.
Copyright © 2014 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BRONJ; Bisphosphonate; Denosumab; Fluorescence-guided bone resection; Osteonecrosis of the jaw; Surgical treatment

Mesh:

Year:  2014        PMID: 25541255     DOI: 10.1016/j.jcms.2014.11.014

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  24 in total

1.  Jaw problems: Update on ARONJ.

Authors:  E Kyriakidou; M Badr; S Harrison; S Atkins
Journal:  Br Dent J       Date:  2015-07       Impact factor: 1.626

2.  Carcinoma of the lip five years after bone marrow transplantation.

Authors:  M Ardore; M Berrone; G Marchitto; S Gandolfo; M Pentenero
Journal:  Ann Stomatol (Roma)       Date:  2015-12-01

3.  Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.

Authors:  Adepitan A Owosho; Ariel Blanchard; Lauren Levi; Arvin Kadempour; Haley Rosenberg; SaeHee K Yom; Azeez Farooki; Monica Fornier; Joseph M Huryn; Cherry L Estilo
Journal:  J Craniomaxillofac Surg       Date:  2015-12-20       Impact factor: 2.078

4.  Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institution's experience.

Authors:  Onur Şahin; Birkan Tatar; Ceren Ekmekcioğlu; Toghrul Aliyev; Onur Odabaşı
Journal:  J Clin Exp Dent       Date:  2020-08-01

5.  Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam.

Authors:  Anton Straub; Andreas Vollmer; Thiên-Trí Lâm; Roman C Brands; Maximilian Stapf; Oliver Scherf-Clavel; Max Bittrich; Andreas Fuchs; Alexander C Kübler; Stefan Hartmann
Journal:  Clin Oral Investig       Date:  2022-08-09       Impact factor: 3.606

6.  Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.

Authors:  P J Voss; D Steybe; P Poxleitner; R Schmelzeisen; C Munzenmayer; H Fuellgraf; A Stricker; W Semper-Hogg
Journal:  Odontology       Date:  2018-04-30       Impact factor: 2.634

Review 7.  Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents.

Authors:  F-J Rodriguez-Lozano; R-E Oñate-Sánchez
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2016-09-01

8.  Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review.

Authors:  Hitoshi Yoshimura; Seigo Ohba; Hisato Yoshida; Kyoko Saito; Kazuyoshi Inui; Rie Yasui; Dai Ichikawa; Minako Aiki; Junichi Kobayashi; Shinpei Matsuda; Yoshiaki Imamura; Kazuo Sano
Journal:  Oncol Lett       Date:  2017-05-04       Impact factor: 2.967

Review 9.  Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).

Authors:  Sven Otto; Suad Aljohani; Riham Fliefel; Sara Ecke; Oliver Ristow; Egon Burian; Matthias Troeltzsch; Christoph Pautke; Michael Ehrenfeld
Journal:  Medicina (Kaunas)       Date:  2021-05-09       Impact factor: 2.430

Review 10.  Clinical impact of bisphosphonates in root canal therapy.

Authors:  Mothanna K AlRahabi; Hani M Ghabbani
Journal:  Saudi Med J       Date:  2018-03       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.